NEW YORK, May 22, 2026, 13:08 (ET)
Privia Health Group shares traded up late Friday morning after the company released results from its annual meeting, a standard update. Investors are watching to see if Privia’s first-quarter growth sticks for the rest of 2026. PRVA was last seen at $22.78, up 0.6%. Stocks climbed ahead of the Memorial Day break. Nasdaq will close on Monday, May 25, for the holiday.
Privia’s stock barely moved as the filing left the operating story untouched. The bigger focus is on the value-based care side, where doctors and networks are paid for keeping costs low and outcomes high, not just for visits. The governance news from Friday is less of a driver here.
Privia said its shareholders voted through all proposals at the May 20 annual meeting. Nancy Cocozza, David King and Francis Soistman were re-elected as Class I directors. Investors also approved executive pay in the advisory vote and backed PricewaterhouseCoopers as 2026 auditor.
Cocozza got 8,463 restricted stock units at $0, according to a Form 4 filed Friday. The filing said it’s an annual equity grant, not a market purchase. The shares vest either the day before the 2027 annual meeting or a year from the grant date.
Operating conditions mattered more in the quarter. Privia Health on May 7 posted a 25.8% jump in first-quarter revenue to $603.8 million. Net income attributable to the company slipped to $3.1 million from $4.2 million. Adjusted EBITDA moved up 36.3% to $36.7 million. Practice collections rose 14.6% to $914.8 million.
The company left its 2026 revenue target unchanged at $2.35 billion to $2.45 billion, with adjusted EBITDA still at $145 million to $155 million. It lifted its estimate for attributed lives—patients covered by value-based contracts with Privia—to 1.60 million to 1.625 million. The company also said about 80% of adjusted EBITDA should convert to free cash flow, the cash left after operations and capital spending.
Privia Health (PRVA) CEO Parth Mehrotra told analysts on the May 7 call that it’s “still early in the year,” and the company will “keep executing every quarter” before making big changes to guidance. CFO David Mountcastle said there’s a “robust pipeline” for expansion both in current and new markets, but said the guidance does not count on new business development.
Mehrotra questioned the idea that risk in Medicare Advantage is all or nothing. He told reporters, “full capitation is not the only way to perform well.” With capitation, providers get a set payment per patient. That model can boost returns if costs stay low but can be painful if medical spending jumps.
Competition is tight. agilon Health pitches a physician-partner approach focused on “value of care, not volume of fees.” Astrana Health calls itself a physician-centric, technology-powered, risk-bearing healthcare manager. For Privia, it comes down to whether provider growth and patient attribution can scale up without bringing in insurer-style medical cost swings. agilon health
But it’s easy to see how things could go wrong. The company points to risks from healthcare regulation, legal issues with medical-group ties, rivals, reimbursement cuts, vendor problems, or privacy and cybersecurity trouble. Any of those could hit margins investors are betting on.
PRVA shares saw a small lift after a low-key governance move, but the main issue isn’t settled yet. Investors are waiting to see if the bump in covered lives actually brings in more dollars, not just more members.
